I shorted the RWLK when it was at IPO hype of $38, and all the way to $16. Most recently, RWLK reported huge sales growth in Q4 (283% YoY growth from $0.4m to $1.5m) and stock prices rose above $18.
If you give a second look at the market and product, the company is not worth $200m. The only product is exoskeleton for people who lost mobility. Similar as EYES, the company has a long way to go from being profitable; current market cap only reflects Irrational exuberance in the sector. Read More »